600211 Tibet Rhodiola Pharmaceutical Holding
- 33.40
- -0.12-0.36%
Tibet Rhodiola Pharmaceutical Holding News
Tibet Rhodiola Pharmaceutical Holding (600211.SH): There is currently no specific plan for overseas sales of their main product, Xinhuosu.
On July 11th, Gloden Investment Network received inquiries from an investor on the investor Q&A platform regarding Tibet Rhodiola Pharmaceutical Holding (600211.SH), asking: "Does the company's main product have the potential and plan to expand overseas? Are there products with similar efficacy overseas?" The company replied that the main product, Xinhuosu, does not currently have a specific plan for overseas sales, but the product Imdur is sold overseas. Public information shows that Xinhuosu and Nesiritide from abroad are both products used for the treatment of acute decompensated heart failure.
Tibet Rhodiola Pharmaceutical Holding (600211.SH): The new production line for Xin Huosu is expected to commence formal production in the second half of the year after registration approval.
According to the investor relations activity records disclosed by Tibet Rhodiola Pharmaceutical Holding (600211.SH) on July 10th, the new production line of Xinhuosu is expected to be put into formal production after registering and approving in the second half of the year, and the total production capacity will reach 15 million units per year. The total investment of the production line is about 0.14 billion yuan. The company is expected to complete the transfer and consolidation next year according to the accounting standards and actual situations, and then depreciate or amortize it for 12 years, which will not have a significant impact on the company's profits.
Tibet Pharmaceutical (600211.SH): The product does not cover the category of synthetic organisms
Gelonghui, May 10 丨 Tibet Pharmaceutical (600211.SH) said on the investor interactive platform that the company's products do not yet cover the category of synthetic organisms.
Tibet Pharmaceutical (600211.SH) announced first-quarter results, net profit of 313 million yuan, up 3.21% year on year
Tibet Pharmaceutical (600211.SH) disclosed its report for the first quarter of 2024. The company achieved revenue of 7.0 during the reporting period...
Tibet Pharmaceutical (600211.SH) plans to distribute 0.737 yuan per share to increase 0.3 shares in 2023, excluding interest on April 30
Tibet Pharmaceutical (600211.SH) announced that the company plans to distribute a cash dividend of 0.737 per share in 2023...
Tibet Pharmaceutical (600211.SH): Since Neoactive entered the medical insurance list in 2017, sales have risen sharply in recent years
Gelonghui, April 10 | Tibet Pharmaceutical (600211.SH) said at the performance briefing that sales of Neoactive have risen sharply in recent years since entering the medical insurance catalogue in 2017. According to the company's 2024 performance guidelines, sales of Neoactive are expected to maintain a continuous growth trend. The company will make every effort to do a good job in product sales and promote the steady growth of business performance.
Tibet Pharmaceutical (600211.SH): Received 86.2 million yuan in industrial support funds
Gelonghui, March 29丨Tibet Pharmaceutical (600211.SH) announced that the company and its subsidiary, Tibet Nordicom Pharmaceutical Co., Ltd. received 86,202,742 yuan in industrial development support funds from the Shannan Happy Home Construction Administration on March 29, 2024, accounting for 10.76% of the company's most recent (2023) audited net profit attributable to shareholders of listed companies.
Tibet Pharmaceutical (600211.SH) reported 2023 results, net profit of 801 million yuan, an increase of 116.56% year-on-year
According to the Zhitong Finance App, Tibet Pharmaceutical (600211.SH) released its 2023 annual report, achieving operating revenue of 3.134 billion yuan, an increase of 22.69% over the previous year. Achieved net profit of 801 million yuan attributable to shareholders of listed companies, an increase of 116.56% over the previous year. Achieved net profit of 784 million yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, an increase of 112.49% over the previous year. Cash of 7.37 yuan (tax included) is distributed to all shareholders for every 10 shares, while 3 shares are added for every 10 shares using the capital reserve fund. During the reporting period, operating income increased by 22.69%, returning net profit to mother
Tibet Pharmaceutical (600211.SH): Nordicom is now gradually showing a better market pattern
Gelonghui, March 11 | Tibet Pharmaceutical (600211.SH) disclosed a record sheet of investor relations activities, showing that the company made market strategy adjustments to Nordicom products in the early stages, and the base for the previous period was low; at the same time, Nordicom is now gradually showing a better market pattern.
Tibet Pharmaceutical (600211.SH): The estimated sales volume of neovactin in 2024 is being calculated based on market demand
Gelonghui March 11 丨 Tibet Pharmaceutical (600211.SH) disclosed an investor relations activity record table showing that judging from the previous sales situation, it is normal for sales to fluctuate monthly and quarterly. Judging from the sales situation throughout the year, the development trend of neovactin will be more accurate. The specific sales data for the previous two months is still being counted. The company is counting the estimated sales volume of neovactin in 2024 based on market demand.
Tibet Pharmaceutical (600211.SH): The promotion fee for Neoactive has been gradually reduced to the current 53% +0.5% incentive fund
Gelonghui, Feb. 28 | Tibet Pharmaceutical (600211.SH) said on the investor interactive platform that Neoactive was marketed in 2005 and promoted by Kangzhe Pharmaceutical in 2008. The promotion service rate was 61%. At this time, the company had no relationship with Kangzhe Pharmaceutical; in February 2014, Kangzhe Pharmaceutical held a total of 5% of the company's shares and became a related party of the company. There will be differences in promotion costs for different products due to differences in market coverage, product development stages, etc. The promotion fee for Neoactive has been gradually reduced to the current 53% +0.5% bonus fund. The company's board of directors and shareholders' meetings are held every year
Tibet Pharmaceutical (600211.SH) posted an advance increase. Net profit for 2023 is expected to be about 800 million yuan, an increase of about 116% over the previous year
Tibet Pharmaceutical (600211.SH) announced that the company expects to achieve net profit of 800 million yuan in 2023...
Tibet Pharmaceutical (600211.SH): Currently, there are no proprietary Chinese medicines in combination with Chuanqiong, Rhodiola, and Astragalus
Gelonghui, December 27丨Tibet Pharmaceutical (600211.SH) said on the investor interactive platform that the company is currently not developing the combined proprietary Chinese medicine of Chuanqiong, Rhodiola, and Astragalus.
Tibet Pharmaceutical (600211.SH) received 53.035 million yuan in industrial support capital
Tibet Pharmaceutical (600211.SH) announced that the company and its subsidiary Tibet Nordicang Pharmaceutical Co., Ltd. in 2023...
Tibet Pharmaceutical (600211.SH): The company's big health products mainly use rhodiola rosea as a raw material
Gelonghui, December 8, Tibet Pharmaceutical (600211.SH) recently stated in receiving research from institutional investors that the company's big health products mainly use rhodiola rosea as raw materials. Currently, the market is still developing and expanding, and there is some sales, but the impact on the company's overall sales revenue is small. In recent years, the market demand for wild rhodiola has continued to increase, and there are many health products using rhodiola rhodiola as a raw material. The company is taking advantage of existing resources to expand and experiment.
Tibet Pharmaceutical (600211.SH): The company continues to carry out research on artificial cultivation of rhodiola rosea at the plateau medicinal herb cultivation base
On December 7, Gelonghui, Tibet Pharmaceutical (600211.SH) said at the performance briefing that the company continues to carry out research on artificial cultivation of rhodiola at the plateau medicinal herb planting site, and is currently conducting cultivation observations on various rhodiola resources, and is currently conducting research on rhodiola hydroponics technology.
Tibet Pharmaceutical (600211.SH): The company will not have any products to participate in the collection in the short term
Gelonghui, December 7, Tibet Pharmaceutical (600211.SH) said at a performance briefing that the company's products will not participate in the collection in the short term; however, in the long run, the company's products may participate in the collection in the future.
Tibet Pharmaceutical (600211.SH): The results of the new active drug health insurance contract renewal negotiations are expected to be announced soon
Gelonghui on December 7, Tibet Pharmaceutical (600211.SH) said at the performance briefing that the results of the new active drug insurance renewal negotiations are expected to be announced soon. Please refer to the announcements of relevant national departments for the final results. Successful contract renewals have a positive effect on the long-term sales of new active ingredients. The company will make every effort to do a good job in product sales and promote steady growth in business performance.
Tibet Pharmaceutical (600211.SH) announced third quarter results, net profit of 259 million yuan, up 43.7% year on year
Tibet Pharmaceutical (600211.SH) released its report for the third quarter of 2023, with revenue of 548 million yuan...
Tibet Pharmaceutical (600211.SH): The domestic market has completed the change of Imdo listing license holder
Glonghui, Oct. 10 | When surveyed by a specific target, Tibet Pharmaceutical (600211.SH) said that Imdo's sales are divided into domestic and overseas markets. The domestic market has completed the change of Imdo listing license holders, and qualified manufacturers have been commissioned to produce Imdo products; at the same time, the company is promoting work related to new API suppliers and pharmaceutical manufacturers. Currently, it has submitted application information to the Drug Evaluation Center of the State Drug Administration and has been accepted. Overseas, due to the fact that it involves more than 40 countries and regions, there are inconsistencies in the transition progress, pharmaceutical administration systems, etc., and some regions and countries are in the process of processing the conversion. Dependency
Analysis
Price Target
No Data
